Research Study

June 18, 2019

Study Presented at American Diabetes Association 79th Scientific Sessions Observed Substantially Less Hypoglycemia With Use of Glytec’s Technology

Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.

Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s eGlycemic Management System® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.

January 15, 2019

At a Cost of $10,405 Per Patient Stay, Hypoglycemia in The Hospital Cannot Be Ignored

A diabetes webinar hosted by the American Hospital Association and sponsored by Glytec showcased why hypoglycemia prevention is imperative to the safety of patients and to the economics of healthcare delivery.

Featured speakers, Dr. Richard Pratley of Florida Hospital System and Dr. Steven Edelman of UC San Diego Health, recently delivered a unified message to several hundred senior healthcare professionals attending an American Hospital Association webinar: Hypoglycemia [low blood sugar] in the hospital is a major patient safety risk with significant clinical and financial implications. A case study presented by Pratley further revealed that insulin-managed patients who experience severe hypoglycemia, or blood sugar less than 40 mg/dL, have longer stays, higher readmission and mortality rates, and an overall cost of care $10,405 greater than patients whose blood sugar remains in the normal range.

November 13, 2018

Study by Riverside Medical Center Shows Reductions in Length of Stay and Hypoglycemia with Glytec’s Insulin Optimization Solution

Presented at the 18th Annual Diabetes Technology Meeting, the study found that patients treated using Glytec’s solution had 73.2% less hypoglycemia and no bounce backs once transferred from a CCU to a general ward.

With a shifting reimbursement landscape and acuity on the rise for hospitalized patients, the need to minimize length of stay and increase throughput in critical care units is a priority for health systems nationwide. A study conducted by Riverside Medical Center of Kankakee, Illinois, the flagship facility of Riverside Healthcare and the area’s only Magnet® recognized institution, found that by using Glytec’s eGlycemic Management System® (eGMS®), patients admitted to critical care units were transferred to general wards .25 days sooner and there were no “bounce backs,” or returns from general wards to critical care units. The study, presented at the 18th Annual Diabetes Technology Meeting, also found that severe hypoglycemia among patients in critical care units was 73.2% lower when using eGMS®.

February 15, 2018

Study Shows Computer-Guided Insulin Dosing Plus More Frequent Blood Glucose Testing Leads to Better Outcomes for Patients with Diabetes

New study in which insulin dosing was guided by Glytec’s Glucommander™ Outpatient observed markedly greater reductions in A1c among patients who tested blood glucose twice a day or more.

A retrospective study being presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) observed that use of Glytec’s Glucommander™ Outpatient for insulin therapy management combined with blood glucose self-testing at least twice a day resulted in better patient outcomes, including a 3.0% absolute reduction in A1c and virtually no hypoglycemia (0.003%) less than 54 mg/dL.

January 23, 2018

Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.

Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.

November 27, 2017

Electronic Glycemic Management Improves Outcomes for Diabetics

According to new data from a quality improvement study, patients with diabetes experienced no diabetes-related readmissions, urgent care visits, or emergency department visits within 30 days of hospital discharge when their healthcare providers used Glytec’s eGlycemic Management System to guide insulin regimens prescribed at discharge.

Researchers at Eastern Virginia Medical School conducted the study and presented their findings earlier this month at the 17th Annual Diabetes Technology Meeting in Bethesda, Maryland.

November 8, 2017

Study Observed Improvements in Transitions of Care Using Hospital-to-Home Diabetes Therapy Management Software from Glytec

New data presented at the 17th Annual Diabetes Technology Meeting observed no diabetes-related readmissions, urgent care visits or emergency department visits within 30 days of hospital discharge when using Glytec’s software.

A prospective quality improvement study led by Eastern Virginia Medical School and presented at the 17th Annual Diabetes Technology Meeting highlights the importance of properly managing transitions of care for patients with diabetes. The study observed that when providers used the Hospital-to-Home (H2H®) module of Glytec’s eGlycemic Management System® to guide insulin regimens prescribed at discharge, patients had no diabetes-related readmissions, urgent care visits or emergency department visits within the first 30 days.

September 23, 2017

Glytec Moves Beyond Clinical Results to Touting Savings

The growing importance of quality ratings will put pressure on hospitals to meet ADA standards for insulin therapy without added manpower.

This June, Glytec came to the American Diabetes Association (ADA) Scientific Sessions with a new story to tell. In years past, Glytec came to ADA armed with data showing that eGMS, a cloud-based glycemic management decision support system, offered a superior way for hospitals to manage insulin therapy for patients. Company officials brought a new focus to the 77th Scientific Sessions in San Diego, California, saying that it’s not enough to offer better time in range. Glytec wants to show how its results translate into what matters most to payers – and a hospital’s bottom line.

September 19, 2017

New Research Shows People on Insulin For Diabetes Maintain A1C Reductions Through Digital Therapy Management

A study presented at EASD 2017 shows long-term A1C reductions through personalized insulin dose adjustments every eight weeks using Glytec’s therapy management software.

More than 50 percent of all people using insulin to manage diabetes are not at their target A1C, which is why this high-risk population is a primary focus of value-based care strategies among providers and payers alike. A retrospective study presented at the Annual Meeting of the European Association for the Study of Diabetes shows that patients whose insulin therapy is guided by Glytec’s FDA-cleared Glucommander™ software not only achieve glucose control rapidly, but with ongoing personalized dose adjustments, successfully maintain A1C reductions long term.

June 21, 2017

With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million

The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.

A decade ago, the American Diabetes Association (ADA) called for hospitals to shift from sliding scale to subcutaneous basal-bolus insulin therapy for non-critically ill patients, but change has been slow in coming. Fear of hypoglycemia and concerns that staff would not be able to keep up with dosing demands of basal-bolus kept hospitals from upgrading to the standard of care.

June 20, 2017

Raymie McFarland Discusses Findings From Glytec’s Basal-Bolus Insulin Study

Glytec’s eGlycemic Management System (eGMS) helped the Kaweah Delta hospital shift its standard of care to basal-bolus insulin, explained Raymie McFarland, vice president of Quality Initiatives at Glytec. Basal-bolus is considered best practice and is safer for patients, but many hospitals have not adopted it due to its difficulty. Glytec hopes its eGMS can change that.

The poster that’s being presented is a case study looking at a 500-plus bed hospital in the San Joaquin Valley of California. It’s a facility named Kaweah Delta Regional Medical Center. Kaweah Delta is a very interesting case in that they did not have expertise from an endocrinology standpoint either in or outside the hospital or the health system facilities.

May 8, 2017

Improving Quality of Care with Electronic Glycemic Management System

At AACE 2017, Jagdeesh Ullal, MD, MS, Eastern Virginia Medical School discussed data from his team’s study that assessed the efficacy of an electronic glycemic management system (eGlycemic Management System) in controlling blood sugars in the hospital setting.

The study was conducted at Wake Forest, but the data was collected across 9 hospitals including about 1600 patients. Ullal explained that patients with diabetes come to the hospital often have high levels of blood sugar. “In our study, the patients, on average, had blood sugar levels of 200 when they came in, and over the course of their stay, their blood sugars were brought back to the normal range (140-180). We were able to achieve that with the eGlycemic Management System software that has also been proven in various other aspects of glucose management in the hospital.”

May 4, 2017

Study Shows Computer-Guided Insulin Titration Enables Basal Bolus Standard of Care

New research presented at the AACE 26th Annual Congress further validates that use of Glytec’s eGlycemic Management System® eliminates barriers to adoption of basal bolus insulin and produces superior patient outcomes.

A multi-center post-hoc analysis presented at the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific & Clinical Congress by Drs. Jagdeesh Ullal and Joseph Aloi demonstrates that Glytec’s eGlycemic Management System® (eGMS®) enables hospitals to achieve the basal bolus standard of care for subcutaneous insulin therapy with extraordinary efficiency and superior patient outcomes. The new research study, entitled ‘AUTO Study, AUtomatic Titration tO Target: Subcutaneous Basal Bolus Insulin Management Using eGMS in the Non-ICU Setting,’ observed a 19% reduction in average daily blood glucose between admission and discharge — with 0.00% severe hypoglycemia < 40 mg/dL -- while achieving the prescribed target blood glucose of 140-180 mg/dL at all mealtime and bedtime intervals.

April 26, 2017

Research Study from Emory University Observes $3,654 Per Patient Cost Savings for CABG Surgery

Drs. Umpierrez and Cardona publish economic and clinical results of the GLUCO-CABG trial, leveraging Glytec’s Glucommander™ for personalized insulin dosing.

A study from Emory University published in the April 2017 issue of Journal of Diabetes and Its Complications (Cardona, et al. 2017) observes a near-20% reduction in perioperative complications, a 1.2-day reduction in ICU stay and a $3,654 reduction in per-patient hospitalization costs for coronary artery bypass graft (CABG) surgery. The reported outcomes, which included no severe hypoglycemia less than 40 mg/dL, were derived from an intensive glycemic control protocol supported by Glytec’s Glucommander™ for personalized insulin dosing.

March 10, 2017

Taking Insulin e-Therapy to Heart

Cardiovascular (CVD) patients receiving personalized insulin therapy using a software-based hyperglycemia management program had dramatically fewer hospital readmissions than those given standard care, according to two studies from Mountain States Health Alliance health care system.

The retrospective studies focused on readmission rates for three patient populations admitted for CVD indications between January and December 2015. The results showed that compared with patients treated with standard care, coronary artery bypass graft patients were readmitted 68% less often with the software program; congestive heart failure patients were readmitted 65% less often; and acute myocardial infarction patients were readmitted 36% less often, the investigators reported at the 2016 Annual Diabetes Technology Meeting.

February 16, 2017

New Research Further Validates Benefits of Personalized Diabetes Therapy Management Across the Continuum of Care

Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.

The 10th Annual International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) showcases additional evidence that use of Glytec’s patented eGlycemic Management System®, or eGMS®, leads to dramatic improvements in diabetes control and patient outcomes in both acute and outpatient settings. Two studies presented by diabetologist and researcher, Dr. Bruce Bode, find that personalized therapy management facilitated through Glytec’s eGMS® effectively reduces hemoglobin A1C, incidence of hypoglycemia and time to prescribed glucose target, all primary measures of diabetes control and patient outcomes.

December 20, 2016

Digital Insulin Management Cuts Hospital Readmissions for CV Patients

The findings come as CMS targets cardiac procedures in both its hospital readmission reduction program and in a bundled payment model set to take effect July 1, 2017.

Glytec, which has FDA clearance for a cloud-based system to manage insulin dosing, selected MSHA as a research site for its electronic glucose management system, or eGMS. According to the studies Parsons and Mumpower presented in November at the Diabetes Technology Meeting showcase, eGMS produced sharp drops in readmission rates in 3 areas of cardiac care.

November 18, 2016

Blood Sugar Monitor System Prevents Avoidable Hospitalization

By identifying patients who needed blood glucose control treatment sooner, readmission costs were significantly reduced.

In a recent study, a health system in Tennessee with 13 hospitals started using eGMS with cardiac patients. The results were impressive. Hospital readmissions for heart attack patients were reduced by more than one third. And the readmission rate for patients with bypass surgery or congestive heart failure was reduced by about two thirds.

November 14, 2016

Dramatic Readmission Reductions for CABG, CHF and AMI Attributed to Glytec’s eGlycemic Management System

Two studies presented at the 16th Annual Diabetes Technology Meeting showcase readmission reductions as high as 68% with Glytec’s solution.

Two new studies presented at last week’s Diabetes Technology Meeting further validate the ability of Glytec’s eGlycemic Management System® (eGMS®) to achieve dramatic readmission reductions for patient populations at the center of new at-risk and value-based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).

October 11, 2016

Study Conducted at Fred Hutch Shows Transplant Patients Benefit from Glytec’s System for Computer-Guided Glucose Management

Study shows hospitalized transplant patients achieve and sustain improved glucose levels when managed on Glucommander from Glytec.

As a pioneer in technology for glycemic management, Glytec is pleased to share the results of a recent study conducted at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The prospective study, led by Cora Espina Erickson, ARNP, CWCN and published by Bone Marrow Transplantation,1 demonstrates that stringent glucose control among allogeneic hematopoietic cell transplantation (HCT) patients is feasible using Glucommander(TM), the computer-guided glucose management system from Glytec.

Page 3 of 5
←
1
...
2
3
4
...
5
→